DM Kendall, MC Riddle, J Rosenstock, D Zhuang, … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Week 30 A1C changes from baseline (±SE) were −0.8 ± 0.1% (10 μg), −0.6 ±
0.1% (5 μg), and +0.2 ± 0.1% (placebo; adjusted P < 0.0001 vs. placebo), yielding placebo-adjusted
reductions of −1.0% (10 μg) and −0.8% (5 μg). In the evaluable population, exenatide- ... Cited by 548 - Related articles - All 11 versions
RA DeFronzo, RE Ratner, J Han, DD Kim, MS … - Diabetes care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A triple-blind, placebo-controlled, 30-week study at
82 US sites was performed with 336 randomized patients. In all, 272 patients completed the
study. The intent-to-treat population baseline was 53 ± 10 years with BMI of 34.2 ± 5.9 ... Cited by 644 - Related articles - All 6 versions
- ►diabetesjournals.org JB Buse, RR Henry, J Han, DD Kim, MS Fineman, … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—At week 30, HbA 1c changes from baseline were −0.86 ± 0.11, −0.46 ± 0.12, and
0.12 ± 0.09% (±SE) in the 10-μg, 5-μg, and placebo arms, respectively (adjusted P < 0.001).
Of evaluable subjects with baseline HbA 1c > 7% (n = 237), 41% (10 μg), 33% (5 μg), and ... Cited by 455 - Related articles - BL Direct - All 13 versions
- ►annals.org [PDF] RJ Heine, LF Van Gaal, D Johns, MJ Mihm, … - Annals of internal …, 2005 - Am Coll Physicians Patients: 551 patients with type 2 diabetes and inadequate gly- cemic control (defined as hemoglobin
A1c level ranging from 7.0% to 10.0%) despite combination metformin and sulfonylurea
therapy. Intervention: Exenatide, 10 g twice daily, or insulin glargine, 1 daily dose titrated ... Cited by 332 - Related articles - BL Direct - All 7 versions
L Blonde, EJ Klein, J Han, B Zhang, SM Mac, … - Diabetes, Obesity & …, 2006 - pt.wkhealth.com Results: Patients completed 82 weeks of exenatide treatment [n = 314, 63% M, age 56 ± 10
years, weight 99 ± 21 kg, body mass index 34 ± 6 kg/m 2 , A1C 8.3 ± 1.0% (mean ± SD)]. Reduction
in A1C from baseline to week 30 [-0.9 ± 0.1% (mean ± SE)] was sustained to week 82 ... Cited by 174 - Related articles - BL Direct - All 6 versions
- ►endojournals.org OG Kolterman, JB Buse, MS Fineman, E Gaines … - Journal of Clinical …, 2003 - Endocrine Soc Despite the advent of new treatments, glucose control in the type 2 diabetes population is
unsatisfactory. AC2993 (synthetic exendin-4; exenatide), a novel glucose-dependent insulinotropic
agent, exhibited notable antidiabetic potential in two clinical studies in patients with type 2 ... Cited by 277 - Related articles - BL Direct - All 6 versions
OG Kolterman, DD Kim, L Shen, JA Ruggles, LL … - American Journal of …, 2005 - ASHP R UGGLES , P H .D., is Associate Director Medical Writing, Medical Af- fairs; L ORETTA L. N
IELSEN , P H .D., is Senior Medical Writer, Medical Affairs; M ARK S. F INEMAN , BS, is Senior
Director, Clinical Affairs; and A LAIN D. B ARON , MD, is Senior Vice-President Research, ... Cited by 141 - Related articles - All 5 versions
- ►diabetesjournals.org MS Fineman, TA Bicsak, LZ Shen, K Taylor, E … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—All three AC2993 regimens led to significant reductions in serum fructosamine relative
to placebo (P ≤ 0.004). Mean reductions ranged from 39 to 46 μmol/l. All AC2993 groups had
reductions in HbA 1c ranging from 0.7 to 1.1% (P ≤ 0.006). An end-of-study HbA 1c <7% ... Cited by 231 - Related articles - BL Direct - All 10 versions
MA Nauck, S Duran, D Kim, D Johns, J Northrup, A … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis The aim of this 52-week, open-label, non- inferiority trial was to compare
the safety and efficacy of exenatide (an incretin mimetic) with that of biphasic insulin aspart. Materials
and methods Patients on metformin and a sulfonylurea were randomised to exenatide (n= ... Cited by 134 - Related articles - BL Direct - All 4 versions
B Ahrén, R Gomis, E Standl, D Mills, A Schweizer - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—In patients randomized to LAF237, baseline HbA 1c averaged 7.7 ± 0.1% and decreased
at week 12 (Δ = −0.6 ± 0.1%), whereas HbA 1c did not change from a baseline of 7.9 ± 0.1%
in patients given placebo (between-group difference in ΔHbA 1c = −0.7 ± 0.1%, P < ... Cited by 313 - Related articles - BL Direct - All 8 versions
